In recent years, advances in protein post-translational modification (PTM) research have revealed histone succinylation as a novel epigenetic modification mechanism critically involved in tumor initiation, progression, and prognosis. Succinylation alters protein physicochemical properties and functions, thereby modulating cellular metabolism, proliferation, and apoptosis. Aberrant histone succinylation in tumor cells demonstrates significant correlations with tumor type, staging, and clinical outcomes, offering new avenues for early cancer diagnosis.

This project utilizes blood serum samples to quantify histone succinylation levels through modification-specific antibody-based detection. Integrated with clinical data, this approach enables early, rapid, and accurate pan-cancer diagnosis, achieving tumor screening via a single-tube blood test. It represents a paradigm shift in precision oncology from "gene-driven" to "epigenetic-metabolic-driven" early detection.

Primary Objective To evaluate differential expression of serum histone succinylation between malignant solid tumor patients and healthy controls, thereby validating its early detection value.

Secondary Objectives

To determine correlations between serum histone succinylation levels and:

Tumor types Tumor stages

To statistically analyze associations of serum histone succinylation with:

Therapeutic efficacy (surgical intervention, radiotherapy, systemic therapy) Clinicopathological variables

Inclusion Criteria:

Case Group:

• Aged ≥18 years, regardless of sex；
• Histologically or cytologically confirmed malignant solid tumors requiring subsequent anticancer therapy；

Control Group:

• Aged ≥18 years, regardless of sex；
• Non-cancer participants enrolled through health screenings；

Exclusion Criteria:

• Pregnant individuals；
• Individuals with serious mental disorders or communication barriers；
• Other conditions deemed by investigators to contraindicate study participation；

Patients with malignant tumors and healthy individuals

2025.08.01-2026.12.31